Your browser doesn't support javascript.
loading
PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer.
Suresh, Samyuktha; Huard, Solène; Brisson, Amélie; Némati, Fariba; Dakroub, Rayan; Poulard, Coralie; Ye, Mengliang; Martel, Elise; Reyes, Cécile; Silvestre, David C; Meseure, Didier; Nicolas, André; Gentien, David; Fayyad-Kazan, Hussein; Le Romancer, Muriel; Decaudin, Didier; Roman-Roman, Sergio; Dubois, Thierry.
Affiliation
  • Suresh S; Breast Cancer Biology Group, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France.
  • Huard S; Breast Cancer Biology Group, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France.
  • Brisson A; Breast Cancer Biology Group, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France.
  • Némati F; Pre-Clinical Investigation Laboratory, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France.
  • Dakroub R; Breast Cancer Biology Group, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France.
  • Poulard C; Laboratory of Cancer Biology and Molecular Immunology, Faculty of Sciences-I, Lebanese University, Hadath, Beirut 1003, Lebanon.
  • Ye M; Cancer Research Center of Lyon, CNRS UMR5286, Inserm U1052, University of Lyon, 69000 Lyon, France.
  • Martel E; Breast Cancer Biology Group, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France.
  • Reyes C; Platform of Experimental Pathology, Department of Diagnostic and Theranostic Medicine, Institut Curie-Hospital, 75005 Paris, France.
  • Silvestre DC; Genomics Core Facility, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France.
  • Meseure D; Breast Cancer Biology Group, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France.
  • Nicolas A; Platform of Experimental Pathology, Department of Diagnostic and Theranostic Medicine, Institut Curie-Hospital, 75005 Paris, France.
  • Gentien D; Platform of Experimental Pathology, Department of Diagnostic and Theranostic Medicine, Institut Curie-Hospital, 75005 Paris, France.
  • Fayyad-Kazan H; Genomics Core Facility, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France.
  • Le Romancer M; Laboratory of Cancer Biology and Molecular Immunology, Faculty of Sciences-I, Lebanese University, Hadath, Beirut 1003, Lebanon.
  • Decaudin D; Cancer Research Center of Lyon, CNRS UMR5286, Inserm U1052, University of Lyon, 69000 Lyon, France.
  • Roman-Roman S; Pre-Clinical Investigation Laboratory, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France.
  • Dubois T; Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France.
Cancers (Basel) ; 14(2)2022 Jan 08.
Article in En | MEDLINE | ID: mdl-35053470
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancers (Basel) Year: 2022 Type: Article Affiliation country: France
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancers (Basel) Year: 2022 Type: Article Affiliation country: France